Table 1.
Exposure pathways used in published experimental cysticercosis infection studies.
Fig 1.
PRISMA 2020 flow diagram for new systematic reviews which included searches of databases, registers and other sources.
*Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers). **If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools. From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71. For more information, visit: http://www.prisma-statement.org/.
Table 2.
Cysticercosis challenge data by exposure pathway.
Table 3.
MLEs for the parameters of the exact beta-Poisson model.
Fig 2.
Exact beta-Poisson dose-response relationship for the “Oral” pathway by type of cyst.
Each graph shows the median (solid black curve) and 95% range (dashed black curves) of the probability of infection as a function of dose, median ID50 infectious dose (dashed black vertical line), and the available data point with its standard deviation (“Proglottids” and “Beetles” pathways only). (A) Development of any (viable or degenerated) cyst. (B) Development of viable cysts. (C) Development of brain cysts.
Fig 3.
Exact beta-Poisson dose-response relationship for the “Eggs” pathway by type of cyst.
Each graph shows the median (solid black curve) and 95% range (dashed black curves) of the probability of infection as a function of dose, median ID50 infectious dose (dashed black vertical line), and the available data point. (A) Development of any (viable or degenerated) cyst. (B) Development of viable cysts. (C) Development of brain cysts.
Table 4.
Estimated doses necessary to cause a 1% and 50% probability (median and 95% range) for the development of any, viable and brain cysts, by exposure pathway.